MISTIE INTRACEREBRAL HEMORRHAGE TRIAL

Does faster clot removal give better patient outcomes in ICH?

  • Home
    Home This is where you can find all the blog posts throughout the site.
  • Categories
    Categories Displays a list of categories from this blog.
  • Tags
    Tags Displays a list of tags that have been used in the blog.
  • Bloggers
    Bloggers Search for your favorite blogger from this site.
  • Archives
    Archives Contains a list of blog posts that were created previously.
  • Login
    Login Login form
42

b2ap3_thumbnail_Cursor_and_MISTIE-III.pngThe new MISTIE-III mobile application is finished and just waiting for it to appear on the Apple and Android App stores.  

In the meanwhile, you can use it via this weblink:  http://braininjuryoutcomes.com/mistie-mobile/web/mistie.php

The MISTIE MOBILE APP has the following features:

  • A link to the VISION EDC
  • Important Phone Numbers
  • Surgical Review Checklist
  • Inclusion/Exclusion Criteria
  • Schedule of Evaluations
  • Protocol at a Glance
  • ABC/2 Calculator
  • Dosing Guidance
  • NIH Stroke Scale Calculator
  • Modified Rankin Assessment
  • Stability Decision-making
  • Prohibited Medications
  • Catheter Tract Algorithm

 

19

Dr. David Newman-Toker and the Brain Injury Outcomes (BIOS) coordinating center at Johns Hopkins University are happy to announce that The National Institute on Deafness and Other Communication Disorders (NIDCD), one of the National Institutes of Health (NIH), has awarded funding for the AVERT clinical trial (FAIN U01DC013778). AVERT (Acute Video-oculography for vertigo in Emergency rooms for Rapid Triage) is a randomized controlled trial evaluating the algorithmic application of a diagnostic medical device (video-oculography or VOG)  in the triage of patients presenting to hospital emergency departments with vertigo and dizziness.

The study is expected to randomize 226 patients across 3 U.S.-based clinical sites. The study has been deemed a non-significant risk device trial by the U.S. FDA as it involves a new (investigational) application of this device. VOG devices are currently FDA-approved for measuring eye movements in the assessment of vestibular conditions; they have not been used extensively in the emergency department setting prior to this trial. The study is currently under review by the Institutional Review Boards at the participating sites and is expected to start enrolling next year.

Continue reading
303

The 12th Annual Neurocritical Care Society (NCS) Meeting will be held this year in Seattle on 11-14 September. There will be a comprehensive session on intracerebral hemorrhage, including reviews of exciting recent advances in the translational, epidemiological and clinical areas. 

Friday’s focus on ICH will provide cutting-edge science, clarity in the practice of complex clinical problems, and maybe even stir up a little controversy. Our MISTIE/CLEAR Lead Investigator, Dr. Daniel F. Hanley, will be speaking as well, on interventional treatment so you don't want to miss it. Click here for details.

939

The 12th Annual Neurocritical Care Society (NCS) Meeting will be held this year in Seattle on 11-14 September. There will be a comprehensive session on intracerebral hemorrhage, including reviews of exciting recent advances in the translational, epidemiological and clinical areas. 

Friday’s focus on ICH will provide cutting-edge science, clarity in the practice of complex clinical problems, and maybe even stir up a little controversy. Our MISTIE/CLEAR Lead Investigator, Dr. Daniel F. Hanley, will be speaking as well, on interventional treatment so you don't want to miss it. Click here for details.

328

In collaboration with the Johns Hopkins University School of Medicine Office of Continuing Medical Education, we now provide continuing medical education (CME) credits, specifically AMA PRA Category 1 Credit™, for completing the online MISTIE-III investigator training courses.   You may earn up to 9 hours, but you must take a specific set of courses. You must also be a registered user of this site.

Brain Injury Outcomes

Johns Hopkins University
1550 Orleans Street
CRB-II, 3M50 South
Baltimore, MD 21231 USA
Office:   (410) 614-6996
Fax: (410) 502-7869
 
24-Hr: (410) 736-1368